Neuland Laboratories Ltd

Neuland Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Neuland Laboratories Ltd

₹ 17,088 1.88%
29 May - close price
neulandlabs.com BSE: 524558 NSE: NEULANDLAB
About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Key Points

Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]

Website BSE NSE
  • Market Cap ₹ 21,924 Cr.
  • Current Price ₹ 17,088
  • High / Low ₹ 19,748 / 11,412
  • Stock P/E 60.4
  • Book Value ₹ 1,454
  • Dividend Yield 0.07 %
  • ROCE 26.6 %
  • ROE 21.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.8% CAGR over last 5 years

Cons

  • Stock is trading at 11.8 times its book value
  • Promoter holding has decreased over last 3 years: -3.50%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Smallcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
407 363 418 393 385 440 311 398 328 293 514 440 776
287 266 280 272 278 316 250 312 278 258 359 363 469
Operating Profit 120 97 137 121 107 124 61 86 51 34 155 77 307
OPM % 29% 27% 33% 31% 28% 28% 20% 22% 15% 12% 30% 18% 40%
8 2 3 2 5 25 4 60 7 8 2 8 12
Interest 4 2 4 4 4 3 1 2 2 5 5 7 7
Depreciation 13 14 15 15 16 16 16 16 17 20 23 24 25
Profit before tax 110 84 121 104 92 130 49 128 39 17 129 54 287
Tax % 23% 25% 27% 22% 27% 25% 34% 20% 29% 21% 25% 26% 26%
85 62 89 81 68 98 32 101 28 14 96 40 213
EPS in Rs 65.87 48.50 69.42 62.90 52.70 76.65 24.91 79.03 21.61 10.69 75.18 31.50 165.64
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
469 510 579 527 667 763 937 951 1,191 1,559 1,477 2,023
402 430 473 477 609 661 790 807 919 1,096 1,147 1,450
Operating Profit 67 80 106 50 58 101 147 144 272 462 330 573
OPM % 14% 16% 18% 10% 9% 13% 16% 15% 23% 30% 22% 28%
0 2 1 4 3 4 16 0 9 12 90 30
Interest 27 24 21 19 16 22 18 13 13 14 8 24
Depreciation 15 16 19 22 26 31 40 49 53 60 66 92
Profit before tax 24 41 67 14 20 52 105 82 215 401 345 488
Tax % 36% 36% 30% 13% 19% 70% 23% 22% 24% 25% 25% 26%
16 26 46 12 16 16 80 64 163 300 259 363
EPS in Rs 17.76 29.73 52.20 13.29 12.58 12.38 62.58 49.52 127.14 233.52 202.21 283.02
Dividend Payout % 9% 7% 0% 0% 0% 16% 8% 10% 8% 6% 6% 12%
Compounded Sales Growth
10 Years: 15%
5 Years: 17%
3 Years: 19%
TTM: 37%
Compounded Profit Growth
10 Years: 30%
5 Years: 39%
3 Years: 30%
TTM: 75%
Stock Price CAGR
10 Years: 36%
5 Years: 52%
3 Years: 84%
1 Year: 49%
Return on Equity
10 Years: 14%
5 Years: 19%
3 Years: 21%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 9 9 9 13 13 13 13 13 13 13 13
Reserves 151 175 534 546 683 693 769 823 975 1,264 1,505 1,853
188 182 192 319 231 264 182 241 128 95 157 301
164 157 150 197 203 260 359 306 463 459 503 761
Total Liabilities 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831 2,178 2,928
123 139 466 475 541 653 716 767 758 824 955 1,178
CWIP 41 40 20 126 104 24 17 20 41 46 48 210
Investments 8 8 8 8 8 8 7 4 1 1 109 2
339 337 392 462 476 545 583 590 781 960 1,066 1,539
Total Assets 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831 2,178 2,928

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
13 45 39 12 70 57 189 60 239 260 317 348
-14 -20 -42 -116 -77 -49 -84 -96 -62 -150 -298 -424
1 -24 -0 105 12 -5 -114 38 -136 -69 25 21
Net Cash Flow 0 1 -3 0 4 2 -9 3 41 41 44 -55
Free Cash Flow -2 26 -2 -121 7 9 84 -37 174 118 112 -49
CFO/OP 33% 71% 52% 29% 129% 60% 133% 56% 104% 80% 119% 79%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 100 85 114 134 90 91 85 90 111 87 78 98
Inventory Days 170 182 188 268 191 209 205 227 211 220 238 247
Days Payable 167 124 123 198 123 114 130 105 135 125 161 135
Cash Conversion Cycle 103 144 179 205 158 186 160 212 187 183 155 210
Working Capital Days 9 24 42 36 136 135 59 72 78 87 74 74
ROCE % 16% 18% 16% 4% 4% 8% 11% 10% 21% 33% 19% 27%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Fixed Asset Turnover
x

Log in to view insights

Please log in to see hidden values.

Login
Number of Active CMS Projects
Count
Total Reactor Volume
Liters
Number of Active US DMFs
Count
Number of Countries Served
Count
Total DMFs Filed Worldwide
Count
R&D Scientist Count
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
36.03% 35.97% 32.80% 32.74% 32.72% 32.64% 32.68% 32.67% 32.67% 32.64% 32.63% 32.63%
20.19% 21.57% 22.69% 24.43% 25.72% 26.46% 23.86% 22.12% 21.69% 20.60% 20.90% 20.46%
6.76% 6.99% 6.02% 6.54% 6.39% 6.38% 9.09% 10.97% 11.57% 13.55% 14.72% 15.84%
0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.00% 0.00%
36.62% 35.08% 38.10% 35.88% 34.77% 34.12% 33.96% 33.85% 33.67% 32.80% 31.76% 31.08%
No. of Shareholders 25,22326,82427,72328,61629,07734,56739,31539,33342,41944,39346,18746,304

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls